Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
Orelabrutinib is the first BTK inhibitor globally to demonstrate efficacy in a Phase II clinical trial for SLE.
Orelabrutinib is the first BTK inhibitor globally to demonstrate efficacy in a Phase II clinical trial for SLE.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.